Esperion announces nomination of ESP-2001 as preclinical development candidate

Esperion (ESPR) announced the nomination of ESP-2001, the Company’s highly-specific allosteric ATP citrate lyase inhibitor, as preclinical development candidate for the treatment of primary sclerosing cholangitis, PSC. With this candidate selection, the Company will begin Investigational New Drug, IND,-enabling studies with a goal to file an IND with the U.S. Food and Drug Administration, FDA, to initiate first-in-human clinical studies in 2026. “The nomination of ESP-2001 marks a pivotal moment in Esperion’s evolution as we expand our therapeutic focus beyond cardiovascular disease,” said Sheldon Koenig, President and Chief Executive Officer of Esperion. “PSC is a devastating condition with no approved treatments, and our preclinical data suggest ESP-2001 has the potential to meaningfully impact disease progression through multiple mechanisms. We are proud to advance a candidate that reflects the capabilities of our next generation ACLY inhibitor program and our commitment to addressing areas of high unmet need.”